| Lipids Management |
1 |
1 |
| Cardiovascular Risk Management |
0 |
1 |
| High Density Lipoprotein (HDL) cholesterol |
0 |
1 |
| Triglycerides |
0 |
0.36 |
| Aminotransferase |
0 |
0.25 |
| Hospital |
0 |
0.25 |
| LDL Cholesterol |
0 |
0.23 |
| Lipoproteins |
0 |
0.14 |
| Liver |
0 |
0.14 |
| Massachusetts |
0 |
0.14 |
| Familial Hypercholesterolemia |
0 |
0.13 |
| Biologic Therapy |
0 |
0.11 |
| Hypercholesterolemia |
0 |
0.11 |
| Monoclonal Antibody |
0 |
0.11 |
| Type 2 Diabetes Mellitus |
0 |
0.1 |
| Cardiometabolic Risk Factors |
0 |
0.08 |
| Grant |
0 |
0.07 |
| Metabolism |
0 |
0.07 |
| Statins |
0 |
0.07 |
| Coronary Artery Disease (CAD) |
0 |
0.05 |
| Apolipoproteins |
0 |
0.04 |
| C-Reactive Protein (CRP) |
0 |
0.04 |
| Cardiovascular disease |
0 |
0.04 |
| Diabetes Mellitus |
0 |
0.04 |
| Hyperlipidemia |
0 |
0.04 |
| Hypertriglyceridemia |
0 |
0.04 |
| Intravenous |
0 |
0.04 |
| Plasma |
0 |
0.04 |
| Refractory |
0 |
0.04 |
| Steatosis |
0 |
0.04 |